gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Trastuzumab binds HER2 on target cells and engages FcγR+ immune effectors (e.g., NK cells) to mediate ADCC, with possible complement-mediated lysis; it also blocks HER2 signaling.
enzyme_product
Off
epitope
On
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Binds domain IV of the HER2 extracellular domain
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06510465
disease_id_num_tar_ref
89
drug_id_num_tar_ref
231